Tariff hikes call for CPOs to keep reputational issues and costs down

At this stage, it is unknown just how much America’s new 10% tariff on the UK will cost the pharmaceutical industry.

However, given that these levies include medical products, businesses can certainly expect to feel an impact from the change.

Blaise Walshe, Procurement Specialist from Barkers Commercial Consultancy, explores how these new tariffs could impact the sector as a whole.

Uncertainty means one thing for large, complex businesses: protecting the share price.

Now is the time for pharmaceutical businesses, wanting to save profits in a volatile environment, to up the ante in managing brand reputations and supplier costs.

This is when Chief Procurement Officers (CPOs) provide value.